Last checked at 15 Dec 2023 17:08
European shares end fifth week higher on rate-cut optimism
Barclays sees first ECB rate cut in April
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News6
GSK Share
Chat18
GSK Share
Trades26,889
GSK
Live RNS4
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,611.00
Bid:
1,610.50
Ask:
1,611.00
Change:
-155.50 (-8.80%)
Spread:
0.50 (0.031%)
Open:
1,616.50
High:
1,637.50
Low:
1,589.50
Prev. Close:
1,766.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Tuesday tips round-up: Royal Dutch Shell, Hyder Consulting, GSK
Tue, 26th Aug 2014 08:31
There is a lot to be said for value-based investment strategies as the year-to-date performance of The Daily Telegraph Questor column's six picks for 2014 show. They have held up despite market turbulence. The old stock market saying "never sell Shell" held true once again, with the shares delivering a total return of 16%, well ahead of the market. Bellway's performance has been less impressive, but the builder is growing earnings and dividends by more than 20% and offers a yield of 3.2%. The shares remain a buy. GlaxoSmithKline has suffered from the bribery allegations in China, which could yet do serious damage. However, the fundamentals remain intact. The group is set to generate over $5bn in free cash flow this year, more than covering its dividend payments. Furthermore, data on final-stage testing for 13 drugs is expected within the next 12 months and the shares trade at a discount to peers Novartis and Astrazeneca. "We are sticking with GSK," Questor says.Shares in Hyder Consulting have done well. The investment column thought the firm might make an attractive target for a takeover and so it was. The stock plummeted following a profit warning but duly bounced back as a bidding war ensued between Dutch rival Arcadis and Japanese engineer Nippon Koei. Microchip manufacturer CSR was selected as its Bluetooth Smart technology might be employed in the new wearable devices which are set to reach the market, such as Google Glass, Nike+ Fuelband and Samsung watches. The shares were dragged down by this year's technology sell-off but Questor is holding firm. Volkswagen stock has struggled, taking a hit from the slowdown seen in the French and German economies but on a price-to-earnings ratio of nine times they still offer excellent value, are at a 10% discount to sector peers and offer a dividend yield of 2.3%."With company profits and stock market valuations near record highs there is little margin for error in the second half but Questor remains confident these value picks will deliver," the column says. Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.AB
More News
15 Dec 2023 16:51
LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools
(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.
Read more15 Dec 2023 16:29
PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg
(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.
Read more12 Dec 2023 10:08
AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal
Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.
Read more12 Dec 2023 08:22
TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine
(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.
Read more12 Dec 2023 07:39
LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI
(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.
Read more12 Dec 2023 07:24
GSK seeks to extend RSV vaccine approval in Japan
(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.
Read more11 Dec 2023 08:28
GSK drug gets EU marketing backing for form of endometrial cancer
(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.
Read more11 Dec 2023 07:41
LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook
(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.
Read more11 Dec 2023 07:23
GSK endometrial cancer treatment gets Europe authorisation
(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.
Read more7 Dec 2023 12:54
THG backer Kelso pushes for demerger to trim "inherent" valuation gap
(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.
Read more5 Dec 2023 10:02
LONDON BROKER RATINGS: Goldman lifts Landsec and British Land
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more27 Nov 2023 09:00
GSK announces positive results from Blenrep phase 3 blood cancer trial
(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.
Read more27 Nov 2023 08:02
GSK receives 'positive' headline results from phase III trial
(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.
Read more22 Nov 2023 09:48
LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Read more